BR0214451A - conjugados do hormÈnio do crescimento humano quimicamente modificado - Google Patents

conjugados do hormÈnio do crescimento humano quimicamente modificado

Info

Publication number
BR0214451A
BR0214451A BRPI0214451-4A BR0214451A BR0214451A BR 0214451 A BR0214451 A BR 0214451A BR 0214451 A BR0214451 A BR 0214451A BR 0214451 A BR0214451 A BR 0214451A
Authority
BR
Brazil
Prior art keywords
human growth
chemically modified
modified human
growth hormone
hormone conjugates
Prior art date
Application number
BRPI0214451-4A
Other languages
English (en)
Inventor
Rory F Finn
Wei Lao
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0214451A publication Critical patent/BR0214451A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

"CONJUGADOS DO HORMÈNIO DO CRESCIMENTO HUMANO QUIMICAMENTE MODIFICADO". A presente invenção refere-se ao hormónio do crescimento humano quimicamente modificado (hGH) preparado pela ligação de um polímero solúvel em água à proteína. A proteína modificada, de acordo com a presente invenção, pode ter uma atividade mais longa em comparação ao hGH não-modificado, permitindo dose reduzida e oportunidades fixadas.
BRPI0214451-4A 2001-11-20 2002-11-20 conjugados do hormÈnio do crescimento humano quimicamente modificado BR0214451A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
PCT/US2002/037270 WO2003044056A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Publications (1)

Publication Number Publication Date
BR0214451A true BR0214451A (pt) 2006-05-30

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0214451-4A BR0214451A (pt) 2001-11-20 2002-11-20 conjugados do hormÈnio do crescimento humano quimicamente modificado

Country Status (25)

Country Link
EP (1) EP1453859A2 (pt)
JP (2) JP2005525302A (pt)
KR (2) KR20050044858A (pt)
CN (1) CN1608079A (pt)
AP (1) AP2004003050A0 (pt)
AU (1) AU2002356990A1 (pt)
BR (1) BR0214451A (pt)
CA (1) CA2467731A1 (pt)
CO (1) CO5580794A2 (pt)
EA (2) EA008505B1 (pt)
EC (1) ECSP045114A (pt)
GE (1) GEP20063860B (pt)
HR (1) HRP20040448A2 (pt)
HU (1) HUP0500997A2 (pt)
IL (1) IL162031A0 (pt)
IS (1) IS7268A (pt)
MA (1) MA27544A1 (pt)
MX (1) MXPA04004809A (pt)
NO (1) NO20042182L (pt)
OA (1) OA13063A (pt)
PL (1) PL374354A1 (pt)
RS (1) RS53104A (pt)
TN (1) TNSN04090A1 (pt)
WO (1) WO2003044056A2 (pt)
ZA (1) ZA200403907B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
WO2003049699A2 (en) * 2001-12-11 2003-06-19 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
ES2566797T3 (es) * 2002-01-18 2016-04-15 Biogen Ma Inc. Compuestos de polímero de polialquileno y usos de éstos
RS20050202A (en) 2002-09-09 2007-08-03 Nektar Therapeuticals Al.Corporation, Water-soluble polymer alkanals
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
CN100580087C (zh) * 2003-10-10 2010-01-13 诺和诺德医疗保健公司 肽的缀合
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
RU2385879C2 (ru) * 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
JP2008511610A (ja) * 2004-08-31 2008-04-17 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー グリセロール分岐のポリエチレングリコール−ヒト成長ホルモン結合体、それらの製造方法及び使用方法
AU2005323106B2 (en) * 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
KR101423769B1 (ko) 2004-12-22 2014-07-30 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 그와관련된 방법 및 그의 용도
EP2284191A3 (en) 2004-12-22 2011-07-20 Ambrx, Inc. Process for the preparation of hGH
JP2008531482A (ja) 2005-02-10 2008-08-14 ノボ ノルディスク アクティーゼルスカブ Ｃ末端がｐｅｇ化された成長ホルモン
JP2008538290A (ja) 2005-04-18 2008-10-23 ノボ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
CA2620638A1 (en) * 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
EP1954710B1 (en) * 2005-11-08 2011-03-02 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
NZ595303A (en) 2005-12-14 2013-03-28 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
KR20100014215A (ko) * 2006-07-07 2010-02-10 노보 노르디스크 헬스 케어 악티엔게젤샤프트 신규 단백질 접합체 및 그것의 제조 방법
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
CA2720306C (en) 2008-04-03 2016-03-15 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
US8273343B2 (en) * 2008-07-31 2012-09-25 Pharmaessentia Corp. Protein-polymer conjugates
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
US8492503B2 (en) * 2008-09-11 2013-07-23 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
TWI504405B (zh) 2009-01-22 2015-10-21 Novo Nordisk Healthcare Ag 穩定的生長激素化合物
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
BR112012014721B1 (pt) 2009-12-15 2022-06-28 Ascendis Pharma Endocrinology Division A/S Composições de hormônio do crescimento, seus métodos de fabricação, recipiente e kit
WO2011089255A1 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
WO2011146518A2 (en) * 2010-05-17 2011-11-24 Cebix Inc. Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
EP4282485A3 (en) 2014-11-06 2024-01-17 PharmaEssentia Corporation Dosage regimen for pegylated interferon
WO2016079302A1 (en) 2014-11-21 2016-05-26 Ascendis Pharma Growth Disorders Division A/S Long-acting growth hormone dosage forms
IL254389B2 (en) * 2015-03-11 2023-03-01 Nektar Therapeutics Polymer conjugates and the il–7 group
CN114805540A (zh) * 2015-09-18 2022-07-29 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
CN114539384A (zh) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
ES2113354T3 (es) * 1990-05-04 1998-05-01 American Cyanamid Co Estabilizacion de somatotropinas y otras proteinas por modificacion de residuos de cisteina.
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1997011178A1 (en) * 1995-09-21 1997-03-27 Genentech, Inc. Human growth hormone variants
NZ502375A (en) * 1997-07-14 2001-11-30 Bolder Biotechnology Inc The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family
AU775937B2 (en) * 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL144361A0 (en) * 1999-01-29 2002-05-23 Hoffmann La Roche Gcsf conjugates
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
EP1352062A2 (en) * 2001-01-11 2003-10-15 Maxygen Aps Improved growth hormone molecules

Also Published As

Publication number Publication date
MA27544A1 (fr) 2005-10-03
ECSP045114A (es) 2004-07-23
HRP20040448A2 (en) 2006-02-28
NO20042182L (no) 2004-08-11
IL162031A0 (en) 2005-11-20
TNSN04090A1 (fr) 2006-06-01
EA200400565A1 (ru) 2005-06-30
JP2006321808A (ja) 2006-11-30
IS7268A (is) 2004-05-17
CA2467731A1 (en) 2003-05-30
WO2003044056A3 (en) 2003-08-21
EA008505B1 (ru) 2007-06-29
JP2005525302A (ja) 2005-08-25
EA200700431A1 (ru) 2008-02-28
PL374354A1 (en) 2005-10-17
GEP20063860B (en) 2006-06-26
ZA200403907B (en) 2007-12-27
CN1608079A (zh) 2005-04-20
HUP0500997A2 (en) 2007-11-28
AP2004003050A0 (en) 2004-06-30
WO2003044056A2 (en) 2003-05-30
MXPA04004809A (es) 2004-08-11
CO5580794A2 (es) 2005-11-30
KR20050044858A (ko) 2005-05-13
KR20070072924A (ko) 2007-07-06
AU2002356990A1 (en) 2003-06-10
EP1453859A2 (en) 2004-09-08
RS53104A (en) 2006-10-27
OA13063A (en) 2006-11-10

Similar Documents

Publication Publication Date Title
BR0214451A (pt) conjugados do hormÈnio do crescimento humano quimicamente modificado
BR0316716A (pt) Conjugados quimicamente modificados do hormÈnio do crescimento humano
NO20064676L (no) Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre
RS20050066A (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
ATE195721T1 (de) Lipopolyamine als transfectionsmittel und ihre pharmazeutischen anwendungen
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
BG102714A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
WO1996023526A3 (en) Diagnostic imaging contrast agents with extended blood retention
BR9610386A (pt) Utilização de um composto capaz de antagonizar, ao menos parcialmente, a atividade oncogênica da proteína mdm2, utilização de um scfv, dirigido contra o domínio 1-134 da proteína mdm2, utilização de um ácido nucléico codificado para um composto capaz de antagonizar a atividade oncogênica da proteína mdm2, vetor viral e composição farmacêutica
DK0971600T3 (da) Medicinsk levnedsmiddel til diabetikere
BR0212522A (pt) Ligando de ligação de zinco, hexâmero de insulina, preparação aquosa de insulina e métodos de prolongar a ação de uma preparação de insulina e de preparar um ligando de ligação de zinco
BR0008403A (pt) Formulação farmacêutica para administração oral
BR9911871B1 (pt) derivados de ácido fenoxiacético e composições farmacêuticas contendo os mesmos.
BG106046A (en) Pharmaceutical compositions of ertythropoietin
DE60140426D1 (de) Pharmazeutische zusammensetzung für muskelanabolismus
WO2002056893A8 (en) Novel receptors for $i(helicobacter pylori) and use thereof
NO20023551L (no) Ibuprofen-inneholdende aktivt middel-preparat
WO2002070014A8 (en) Compositions comprising an o/w emulsion containing conjugated linoleic acid
BR0212287A (pt) Proteìna de ligação caspase-8, sua preparação e uso
BR0211192A (pt) Conjugados de progenipoietina quimicamente modificados
BR0211991A (pt) HormÈnio do crescimento humano modificado
TR199700963T1 (xx) Kardiyovask�ler hastal�klar�n tedavisi i�in aminotetralin t�revi.
BR0013840A (pt) Análogos monoméricos de insulina humana
WO2001024803A3 (en) Pharmaceutical compositions containing copper, salicylic acid and vitamines c
BR0113814A (pt) Amidas de ácido fenilciclohexanocarboxìlico e sua aplicação

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.

B15K Others concerning applications: alteration of classification

Ipc: C07K 14/61 (2006.01), A61K 47/60 (2017.01)